Paul Kalra

Oct 25, 2024 | onlinelibrary.wiley.com | Paul Foley |Paul Kalra |John Cleland |Mark C. Petrie

Introduction Iron deficiency is common in patients with heart failure and clinical trials suggest that correction with high-dose intravenous (IV) iron improves symptoms and quality of life and reduces the risk of heart failure hospitalization.1-3 There is a theoretical risk that iron supplements might increase the risk or severity of infection.

Mar 28, 2024 | onlinelibrary.wiley.com | Kieran F. Docherty |John McMurray |Paul Kalra |John G.F. Cleland

Introduction Iron deficiency is common in patients with heart failure and is associated with anaemia and a poorer prognosis.

Jun 6, 2023 | cfrjournal.com | Harriette Van Spall |James L. Januzzi |Paul Kalra

ESC-HFA 2023 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US)  to discuss the findings of the TRACER-HF trial. Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients.